Original Research Article
Year: 2019 | Month: October | Volume: 6 | Issue: 10 | Pages: 378-384
Monitoring Hypertension with Azilsartan Treatment With/Without Added Drug in Patients With/Without Comorbidity: An Observational Study
Preeti Gupta1, Sandeep Bansal2, Anunay Gupta1
1Assistant Professor, 2Professor and Head,
Department of Cardiology, Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, Ministry of Health and Family Welfare, Government of India, New Delhi- 110029, India.
Corresponding Author: Preeti Gupta
ABSTRACT
Aims and Objectives of Study: Hypertension statistics had reported that approximately 9 million lives/per annum are at risk due to increased blood pressure. Azilsartan Medoxomil is an angiotensin inhibitor, widely used as a single treatment regime or in combination with other drugs is an FDA approved therapeutic that has a significant impact in hypertension patients. The present study is a prospective observational study with (a) Primary objective: to evaluate efficiency of Azilsartan (40mg / 80mg) as single treatment regime or with added drug, (b) Secondary objective: to assess the control statistics of hypertension in patients with/ without comorbidity.
Methodology: A total of 120 patients were screened and 100 subjects fulfilled the inclusion criteria with a hypertensive cut off value of 130/80 mmHg. Patients were subjected to Azilsartan monotherapy dosage (40mg/80mg) and combinatorial Azilsartan treatment with added drug. The following data was collected and analyzed for all study subjects enrolled in this observational study: Demographic details, Comorbidity associated with hypertension, Measurements of Systolic blood pressure (SBP), Diastolic blood pressure (DBP), Measurements of Systolic blood pressure (SBP3m) and Diastolic blood pressure (DBP3m) after 3 months of drug treatment.
Results: The study population was predominantly of 51-60 years age group. Prevalence of hypertension at a gender level clearly showed that male population with 63% enrollment in study are at an increased risk in comparison to 37% patient enrollment noted in female population. Medical comorbidity ailments including Coronary Artery Disease, Diabetes Mellitus, Rheumatic Heart Disease. Azilsartan dosage (40mg/80mg) with either single treatment regime or combinatorial treatment regime with added drugs caused effective reduction in blood pressure during the study period.
Conclusion: Combinatorial treatment regimens of Azilsartan (40mg/80mg) along with added drug, proved more effective in significantly lowering blood pressure levels.
Key words: Blood Pressure, Hypertension, Azilsartan, Comorbidity, Risk factors, Coronary artery disease(CAD), Diabetes mellitus, CAD/DM, Rheumatic heart disease (RHD).
[PDF Full Text]